Finland· FI-REL-REL61289
SIILTIBCY
A mycobacterium tuberculosis, rekombinante antigene product containing recombinant dimer of mycobacterium tuberculosis 6 kda early secretory antigenic target (rdesat-6) + recombinant 10 kda culture filtrate protein of mycobacterium tuberculosis (rcfp-10), registered in Finland by Serum Life Science Europe GmbH. The same ATC class is registered in 2 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Mycobacterium tuberculosis, rekombinante antigene is registered in 2 of 19 countries.
Countries holding a registration under ATC V04CF02 (mycobacterium tuberculosis, rekombinante antigene), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 2 of them publish a price we can compare per daily dose
Mycobacterium tuberculosis, rekombinante antigene · ATC V04CF02
2 / 19 countries
- Czechiaprice
- Finlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Recombinant dimer of Mycobacterium tuberculosis 6 kDa early secretory antigenic target (rdESAT-6) + Recombinant 10 kDa culture filtrate protein of Mycobacterium tuberculosis (rCFP-10)
- Manufacturer
- Serum Life Science Europe GmbH
- Country
- Finland (FI)
- ATC code
- V04CF02
- ATC class
- Mycobacterium tuberculosis, rekombinante Antigene
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under V04CF02
Mycobacterium tuberculosis, rekombinante antigene, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/95fec2e3-31d7-4deb-9751-dace8225e58f GET /v1/drugs/95fec2e3-31d7-4deb-9751-dace8225e58f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, liuos",
"route": "Ihon sisään",
"ddd_unit": null,
"strength": "(0.5 mikrog + 0.5 mikrog) / ml",
"atc_label": "mycobacterium tuberculosis, rekombinanttiantigeenit",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/24/1882/001-002",
"fimea_rel_id": "REL61289",
"authorised_at": "2025-01-13"
}See everything about mycobacterium tuberculosis, rekombinante antigene.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.